Lynx1 Capital Management LP 13D and 13G filings for Allogene Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-02-14 09:02 am Purchase | 2024-12-31 | 13G | Allogene Therapeutics, Inc. ALLO | Lynx1 Capital Management LP | 10,874,723 5.200% | 10,874,723 (New Position) | Filing |